Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

References

• PovsicM, EnstoneA, WynR, KornalskaK, PenrodJR, YuanY. Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: a systematic literature review (SLR). PLoS One. 2019;14(7):e0219622. doi:10.1371/journal.pone.021962231318909
   PubMed Web of Science ®Google Scholar
• EpsteinRS, AaproMS, BasuUK, et al. Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors. Adv Ther. 2020;37(8):3606–3618. doi:10.1007/s12325-020-01419-632642965
   PubMed Web of Science ®Google Scholar
• CrawfordJ, DaleDC, LymanGH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–237. doi:10.1002/cncr.1188214716755
   PubMed Web of Science ®Google Scholar
• BryerE, HenryD. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. Int J Clin Transfus Med. 2018;6:21–31. doi:10.2147/IJCTM.S187569
   Google Scholar
• WeyckerD, HatfieldM, GrossmanA, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019;19(1):151. doi:10.1186/s12885-019-5354-530764783
   PubMed Web of Science ®Google Scholar
• CrawfordJ, DenduluriN, PattD, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer. 2020;28(2):925–932. doi:10.1007/s00520-019-04875-131172284
   PubMed Web of Science ®Google Scholar
• LiouSY, StephensJM, CarpiucKT, FengW, BottemanMF, HayJW. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007;27(6):381–396. doi:10.2165/00044011-200727060-00002
   PubMed Web of Science ®Google Scholar
• BalducciL, ExtermannM. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–237. doi:10.1634/theoncologist.5-3-22410884501
   PubMedGoogle Scholar
• BalducciL, HardyCL, LymanGH. Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control. 2000;7(6):539–547. doi:10.1177/10732748000070060511088062
   PubMedGoogle Scholar
• LymanGH, KudererNM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003;1(1):23–35. doi:10.3816/SCT.2003.n.00218628128
   PubMedGoogle Scholar
• LymanGH, LymanCH, AgboolaO. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10(6):427–437. doi:10.1634/theoncologist.10-6-42715967836
   PubMed Web of Science ®Google Scholar
• TalcottJA, SiegelRD, FinbergR, GoldmanL. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10(2):316–322. doi:10.1200/jco.1992.10.2.3161732432
   PubMed Web of Science ®Google Scholar
• AartsMJ, AertsJG, van den BorneBE, BiesmaB, LemmensVE, KlooverJS. Comorbidity in patients with small-cell lung cancer: trends and prognostic impact. Clin Lung Cancer. 2015;16(4):282–291. doi:10.1016/j.cllc.2014.12.00325572007
   PubMed Web of Science ®Google Scholar
• ChaoC, PageJH, YangSJ, RodriguezR, HuynhJ, ChiaVM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014;25(9):1821–1829. doi:10.1093/annonc/mdu20324915871
   PubMed Web of Science ®Google Scholar
• ChiaVM, PageJH, RodriguezR, YangSJ, HuynhJ, ChaoC. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Breast Cancer Res Treat. 2013;138(2):621–631. doi:10.1007/s10549-013-2454-923468242
   PubMed Web of Science ®Google Scholar
• MorrisonVA, PicozziV, ScottS, et al.; Oncology Practice Pattern Study Working Group. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2(1):47–56. doi:10.3816/clm.2001.n.01111707870
   PubMedGoogle Scholar
• LymanGH, MorrisonVA, DaleDC, et al.; OPPS Working Group; ANC Study Group. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44(12):2069–2076. doi:10.1080/104281903100011926214959849
   PubMed Web of Science ®Google Scholar
• IntragumtornchaiT, SutheesophonJ, SutcharitchanP, SwasdikulD. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2000;37(3–4):351–360. doi:10.3109/1042819000908943510752986
   PubMed Web of Science ®Google Scholar
• LymanGH, AbellaE, PettengellR. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–199. doi:10.1016/j.critrevonc.2013.12.00624434034
   PubMed Web of Science ®Google Scholar
• SeoSH, KimSE, KangYK, et al. Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer. 2016;16(1):900. doi:10.1186/s12885-016-2934-527863481
   PubMed Web of Science ®Google Scholar
• VincentM, DranitsarisG, VermaS, et al. The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy. Support Care Cancer. 2007;15(3):265–272. doi:10.1007/s00520-006-0154-217120069
   PubMed Web of Science ®Google Scholar
• Barrett-LeePJ, LudwigH, BirgegårdG, et al.; European Cancer Anaemia Survey Advisory Board and Participating Centers. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology. 2006;70(1):34–48. doi:10.1159/00009167516493206
   PubMed Web of Science ®Google Scholar
• CoiffierB, GuastallaJP, Pujade-LauraineE, BastitP; Anemia Study Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer. 2001;37(13):1617–1623. doi:10.1016/s0959-8049(01)00169-111527686
   PubMed Web of Science ®Google Scholar
• LymanCH, CrawfordJ, KudererNM, et al. A conditional risk model for chemotherapy-induced anemia (CIA) in cancer patients. Blood. 2007;110(11):372. doi:10.1182/blood.V110.11.372.372
   Web of Science ®Google Scholar
• Ray-CoquardI, Le CesneA, RubioMT, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol. 1999;17(9):2840–2846. doi:10.1200/jco.1999.17.9.284010561360
   PubMed Web of Science ®Google Scholar
• BisiJE, SorrentinoJA, RobertsPJ, TavaresFX, StrumJC. Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression. Mol Cancer Ther. 2016;15(5):783–793. doi:10.1158/1535-7163.Mct-15-077526826116
   PubMed Web of Science ®Google Scholar
• HeS, RobertsPJ, SorrentinoJA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017;9(387):eaal3986. doi:10.1126/scitranslmed.aal398628446688
   PubMed Web of Science ®Google Scholar
• WeissJM, CsosziT, MaglakelidzeM, et al.; G1T28-02 Study Group. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized Phase II trial. Ann Oncol. 2019;30(10):1613–1621. doi:10.1093/annonc/mdz27831504118
   PubMed Web of Science ®Google Scholar
• DanielD, KuchavaV, BondarenkoI, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled Phase II trial. Int J Cancer. 2020;148(10):2557–2570. doi:10.1002/ijc.33453
   PubMed Web of Science ®Google Scholar
• HartLL, FerrarottoR, AndricZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350–365. doi:10.1007/s12325-020-01538-033123968
   PubMed Web of Science ®Google Scholar
• WeissJ, GoldschmidtJ, AndricZ, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;2:64. doi:10.1016/j.cllc.2021.03.010
   Web of Science ®Google Scholar
• WeissJM, SkaltsaK, GwaltneyC, et al. Positive effects of trilaciclib on patient myelosuppression-related symptoms and functioning: results from three phase 2 randomized, double-blind, placebo-controlled small cell lung cancer trials. Presented at: MASCC/ISOO Annual Meeting: San Francisco, CA, USA; 2019.
   Google Scholar
• CellaD, EtonDT, FaircloughDL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol. 2002;55(3):285–295. doi:10.1016/s0895-4356(01)00477-211864800
   PubMed Web of Science ®Google Scholar
• CellaD, EtonDT, LaiJS, PetermanAH, MerkelDE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24(6):547–561. doi:10.1016/s0885-3924(02)00529-812551804
   PubMed Web of Science ®Google Scholar
• YostKJ, EtonDT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28(2):172–191. doi:10.1177/016327870527534015851772
   PubMed Web of Science ®Google Scholar
• ButtZ, WebsterK, EisensteinAR, et al. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy-Lung scale. Hematol Oncol Clin North Am. 2005;19(2):389–420. doi:10.1016/j.hoc.2005.02.00915833412
   PubMed Web of Science ®Google Scholar
• ZouG. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–706. doi:10.1093/aje/kwh09015033648
   PubMed Web of Science ®Google Scholar
• LudbrookJJ, TruongPT, MacNeilMV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys. 2003;55(5):1321–1330. doi:10.1016/s0360-3016(02)04576-512654444
   PubMed Web of Science ®Google Scholar
• Janssen-HeijnenMLG, MaasHAAM, van de SchansSAM, CoeberghJWW, GroenHJM. Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it?Ann Oncol. 2011;22(4):821–826. doi:10.1093/annonc/mdq44820929965
   PubMed Web of Science ®Google Scholar
• WilliamsGR, MackenzieA, MagnusonA, et al. Comorbidity in older adults with cancer. J Geriatr Oncol. 2016;7(4):249–257. doi:10.1016/j.jgo.2015.12.00226725537
   PubMed Web of Science ®Google Scholar
• YuenAR, ZouG, TurrisiAT, et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000;89(9):1953–1960. doi:10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y11064352
   PubMed Web of Science ®Google Scholar
• SchildSE, StellaPJ, BrooksBJ, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer. 2005;103(11):2349–2354. doi:10.1002/cncr.2103415852407
   PubMed Web of Science ®Google Scholar
• CrawfordJ, KosmidisPA, HirschFR, LangerCJ. Targeting anemia in patients with lung cancer. J Thorac Oncol. 2006;1(7):716–725.17409943
   PubMed Web of Science ®Google Scholar
• KalemkerianGP, AkerleyW, BognerP, et al.; National Comprehensive Cancer Network. Small cell lung cancer. J Natl Compr Canc Netw. 2013;11(1):78–98. doi:10.6004/jnccn.2013.001123307984
   PubMed Web of Science ®Google Scholar
• Di MaioM, PerroneF. Quality of life in elderly patients with cancer. Health Qual Life Outcomes. 2003;1:44. doi:10.1186/1477-7525-1-4414525617
   PubMedGoogle Scholar
• SorrentinoJA, BisiJE, ThompsonD, et al. Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models. presented at: EORTC, NCI, and AACR symposium. Eur J Cancer. 2018;103(suppl 1):e23–e147.
   Google Scholar